Objective: We enterally administered a 14-day course of 3-mercapto-Dvaline (D-penicillamine) to five extremely low birth weight (ELBW) neonates, as a step toward assessing this therapy as a means of reducing the incidence or severity of retinopathy of prematurity (ROP).
Introduction
Retinopathy of prematurity (ROP) is a common retinal neovascular disorder of premature infants. 1, 2 It is of variable severity and sometimes heals spontaneously with no sequelae. However, ROP can progress to retinal detachment or severe retinal scar formation and partial or total vision loss. The National Eye Institute of the National Institutes of Health estimates that ROP affects about 12 000 in 14 000 neonates, and it is the cause of complete blindness of 400-600 neonates annually, in the USA. 3 Extremely low birth weight (ELBW, p1000 g) neonates, particularly those p28 weeks gestation at birth, are at risk for ROP on the basis of their incompletely vascularized retinas. Damage in the avascular retina is thought to induce production of vasogenic factors such as vascular endothelial growth factor (VEGF), which stimulate neovascularization near the surface of the retina. The neovascularization can be followed by fibrosis and subsequent contraction of the scar tissue, leading to traction and retinal detachment. 4, 5 Reactive oxygen species are candidates for causing the initial retinal injury. [6] [7] [8] As a chelator of pro-oxidant heavy metals, 3-mercapto-D-valine has the potential to reduce the amount of free radical activity in the tissues of the premature infant. In addition, 3-mercapto-D-valine can decrease the bioavailability of VEGF by reducing its disulfide bonds. [9] [10] [11] [12] [13] [14] Over an 8-year period (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) while studying the administration of intravenous D-penicillamine to prevent or treat hyperbilirubinemia, Lakatos et al.
15,16 noted a low incidence of ROP among the treated infants. Two clinical trials from Hungary were subsequently reported in which D-penicillamine was administered to preterm neonates in an effort to reduce ROP. In both the trials, the incidence of ROP was significantly reduced and the treatment had minimal toxicity. In a recent Cochrane Review, Drs Phelps, Lakatos, and Watts concluded that insufficient data exists for recommending D-penicillamine prophylaxis in clinical practice. 17 They wrote of the need for appropriately powered and well-designed multicentered trials to test this promising approach.
As no intravenous or liquid form of 3-mercapto-D-valine exists with which to conduct a study, 17 we undertook a pilot feasibility trial, producing a suspension from capsules.
Methods

Participants
Patients were deemed eligible to participate if they weighed p1000 g at birth. Owing to variability in scales, a one-ounce (30 g) tolerance was permitted, allowing the weight on the delivery-room scale to be as high as 1030 g. Patients had to be p30 weeks gestation and either delivered at McKay-Dee Hospital or transported in time to the McKay-Dee Hospital to receive the first dose of study drug by 48 h after birth. Patients were ineligible to participate if they were already enrolled on another research study or if the attending neonatologist declared that the patient was 'unlikely to survive'.
For comparison of safety outcomes, a cohort of neonates with birth weights ranging from 800 to 1000 g and gestational age 26- Table 2 Abnormal laboratory tests among the study subjects and the historic cohort
Patient # Creat >1.5 mg/dl Platelets <100 000/ml ANC <1000/ml Total bili >10 mg/dl Direct bili >2.0 mg/dl Creat ¼ creatinine; ANC ¼ absolute neutrophil count; bili ¼ bilirubin; ALT ¼ alanine amino transferase; AST ¼ aspartate amino transferase. a Patient #3 had maternal autoimmune thrombocytopenia. His mother had ITP and she was treated with IVIG and prednisone before and during pregnancy. The neonate received IVIG once on the first day of life, with a platelet count of 21 000/ml, and he received three platelet transfusions over the first week of life. The thrombocytopenia resolved by 24 days of age. The maximum total serum bilirubin concentration measured in this patient was 12.4 mg/dl, on the third day of life. This was the only bilirubin concentration recorded in excess of 10 mg/dl. b Patient #4 had one mildly elevated AST (77 U/l) on day 34 of life. The value had been normal (24 U/l) on day 31 of life and was again normal (47 U/l) when rechecked on day 37 of life. During this period the ALT remained normal, ranging from 13 to 19 U/l. . The excipients included D&C YELLOW no. 10, gelatin, lactose, magnesium stearate, titanium dioxide, and iron oxide. The capsules were compounded into a suspension (by JTH) as follows: a 100 mg/ml solution was made by using 10 Cuprimine s 250 mg capsules, emptying the powder into a mortar, making certain it was a fine powder with no clumps; to this, 5 ml of Ora-Plus (Paddock Labs, Minneapolis, MN, USA) was added to make a uniform paste; to this, 20 ml of sterile water was added, mixing until all drug appeared to dissolve into a uniform suspension. In preliminary studies, the suspension was stored for up to 30 days in the research pharmacy refrigerator, with weekly removal of aliquots for bacterial culture, pH determination, and refractive index measurement. No microbial contamination, pH change, or apparent degradation was detected over this period. The suspension for clinical use was poured into an amber bottle; with proper labeling of drug name, concentration, recipe, statements 'Shake Well' and 'Refrigerate', and an expiration of 30 days refrigerated.
Outcomes
During each of the 14 days of study drug administration, the bedside NICU nurse recorded possible signs of immediate intolerance of the study drug, using a study checklist kept in a bedside logbook. Specific attention was given to the following categories: gastrointestinal (emesis, increased abdominal girth, diarrhea, bowel perforation, NEC), affecting vital signs (hypo-or hypertension, brady-or tachycardia, hypo-or hyperthermia), respiratory (hypoxemia, hypercarbia, apnea, acidosis), or a new rash.
Laboratory tests of the study subjects were categorized as renal, hepatic, or hematologic, and were compared with the IHC database of patients for the years 2003 and 2004; the patients at birth, weighed 800-1000 g and were 26-30 weeks gestation. Dichotomous variables (for example, the proportion with vs without a creatinine above 1.5 mg/dl) were compared using a Fisher exact test. A Data Safety Monitoring Board (DSMB) was in place to assess serious adverse events. The DSMB had the authority to halt the study if it appeared that patients were facing the studybased risks.
Scoring of ROP in each patient (by SCR) was standardized according to the ICROP guidelines. 18 The decision to treat with laser surgery was based on the ETROP 'Early Treatment of ROP' guidelines. 19 Outcome was tabulated on the basis of the most severely affected eye.
Results
Study subjects and cohort
Between March and June 2005, seven NICU patients were eligible to participate in the ROP study. One of these families was not approached regarding this study because the patient was already enrolled on another research study. The other six families were approached with the invitation to learn about the ROP study. Five of the six families consented to participate. All five, whose family consented, participated in the study. No patients during this period were considered ineligible on the basis that the attending neonatologist declared that they were 'unlikely to survive'.
The first dose of study drug was administered at a median of 16 h after birth (range, 7-47 h). All five of the study subjects received other medications concomitantly with the D-penicillamine. For instance, beginning on the first day of life, all received ampicillin and gentamicin. In all five, these were discontinued on the third day of life, when cultures were found to be sterile. Also, beginning on the first day of life all five received three daily doses of indomethacin, as part of NICU guidelines for prophylaxis against a patent ductus arteriosus in ELBW neonates. Also, beginning on the first day of life, all five received dopamine as a continuous infusion, for treatment of hypotension. The dopamine infusions continued for 1-3 days. All five received mechanical ventilation.
From the IHC electronic data base repository, we identified all patients in any of the four IHC NICU's, with a date of birth from January 1, 2003 to December 31, 2004, weighing 800-1000 g at birth, with a gestational age of 26-30 weeks. Demographic features of these 139 comparison patients and the five study drug recipients are given in Table 1 . Of the 139 comparison neonates, a From the cohort of 139, 110 patients had one or more retinal examinations for ROP preformed in an IHC hospital, with the results of the examinations recorded in the IHC electronic database. Of the 139, 25 died before an ROP examination was performed. Three of the 139 were transferred to a non-IHC hospital before an ROP examination was performed. One remained in an IHC hospital until discharge but had no ROP examination recorded in the electronic database.
110 had results of one or more ROP examinations recorded in the IHC database. In all, 21 died before an ROP examination was performed. Three of the 139 were transferred to a non-IHC hospital before an ROP examination was performed and one remained in an IHC hospital until discharge, but had no ROP examination recorded in the electronic database.
Feasibility and signs of immediate intolerance
In all five study subjects, every dose of the study drug was administered as planned. All were otherwise 'NPO' during the first 3 days of study-drug administration, because of a NICU policy to withhold enteral feedings during indomethacin administration. At 24 h after the final dose of indomethacin, all five study subjects received enteral nutrition using human milk. When enteral feedings were begun, they were given according to the IHC NICU feeding guidelines, beginning with 1.5 ml/kg of colostrum every 3 h by nasal gastric tube. The study drug was given 1 h before (2 h after) a colostrum/milk feeding.
In no case, even a single dose of study drug was held or postponed because of presumed intolerance. In no case, the study drug was discontinued before the entire 14 days of treatment had been given. No signs of immediate intolerance to the enteral administration were recorded. Specifically, within 4 h of the administration, no instances of emesis, increased abdominal girth, or diarrhea were reported. Similarly, within 1 h of the administration, no decrease in oxyhemoglobin desaturation, tachyor bradycardia, hypo-or hypertension was observed. No new rashes were observed. Table 2 summarizes laboratory determinations, during the entire hospitalization, among the study subjects and the cohort. It appeared that the study subjects did not have a higher occurrence, than that of the cohort, of creatinine elevation, thrombocytopenia, neutropenia, indirect or direct hyperbilirubinemia, or elevation of ALT or AST.
Abnormal laboratory tests
ROP scoring
Retinal findings of the study patients and the cohort are listed in Table 3 . One of the study patients developed transient ROP (stage 1), compared with a 54% incidence of ROP stage I or higher in the cohort. None of the study patients had ROP of stage 3 or higher, compared with a 19% incidence in the cohort.
Discussion
The annual number of new cases of ROP appears to be increasing worldwide, probably as a result of the increasing ability of modern neonatology to save smaller and more immature neonates. 3, 20 Recent attempts to reduce the incidence or severity of ROP have included reducing the external light stimulation (the LIGHT-ROP study) and slightly increasing the oxyhemoglobin saturation (the STOP-ROP study). Neither approach resulted in a significant decrease in the incidence or severity of ROP. 21, 22 Experimental studies conclude that the pathogenesis of ROP involves toxicity of oxygen to the avascular retina and developing retinal capillaries, and that VEGF mediates the abnormal capillary growth that distorts and subsequently scars the retina. [9] [10] [11] [12] [13] 23 Mice with endothelial-specific VEGF inactivation are extremely resistant to developing experimental ROP. 24 Watts, Lakatos, and Phelps theorized that prophylactic Dpenicillamine administration to preterm infants might reduce ROP, due to its properties as an antioxidant and suppressor of VEGF. 17 They cited two studies, both performed in Hungary, where Dpenicillamine administration appeared to significantly reduce ROP, with few adverse effects. In a recent Cochrane Review, they called for studies to determine whether D-penicillamine administration will indeed reduce the incidence or severity of ROP. 17 The Hungarian D-penicillamine studies used an intravenous preparation. 15, 16, 25, 26 However, intravenous D-penicillamine is no longer available. 17 In fact, no solution or suspension of Dpenicillamine is available in the USA. Therefore, we compounded D-penicillamine from capsules to a 100 mg/ml suspension and tested the dose and dosing intervals used in Hungary.
The FDA approved the five subjects of our study. In these five, we sought to assess feasibility, immediate intolerance, and shortterm toxicity, by comparing with a large database from our hospital system. We observed that the administration plan was feasible, and we recognized no immediate intolerance of the solution nor did we observe any evidence of renal, hematologic, or hepatic toxicity. Adverse effects of D-penicillamine have been reported in patients who receive chronic (months to years) treatment for rheumatoid arthritis or Wilson's disease. Those adverse effects include aplastic anemia, thrombocytopenia, agranulocytosis, and collagen-vascular disorders. 27 In contrast to the long courses used in arthritis or Wilson's disease, short courses have been used in children or adults with acute heavy metal overdose, and these short courses have not been associated with adverse effects. Fetuses exposed to D-penicillamine in utero have generally been normal, but an embryopathy was reported in a fetus of one women taking D-penicillamine for Wilson's disease. 28 The affected fetus had cutis laxa, micrognathia, limb contractures, and agenesis of the corpus callosum. Hepatic problems have been observed in fetuses of women with Wilson's disease who were not taking D-penicillamine. 29 The previous reports of D-penicillamine administration to neonatal humans come only from Lakatos 15, 16, 25 and Koranyi. 26 Their studies on at least 140 term and preterm newborns for the treatment of hyperbilirubinemia involved only three with side effects; two had mild erythematous rashes that quickly got resolved with antihistamines, and one had vomiting that resolved when the drug was stopped. In the Hungarian studies, renal and hepatic function was within normal limits, on the few selected infants where these were tested, and growth was not adversely affected. We recognize that long-term adverse effects of D-penicillamine administration to preterm neonates are possible, and we know that short-term adverse effects might emerge in large, randomized, placebo-controlled trials. However, based on our experience and the previous Hungarian trials, we suggest that clinical trials testing enteral 3-mercapto-D-valine as a means of reducing ROP should go forward.
